Icosavax, Inc. (ICVX)
Feb 20, 2024 - ICVX was delisted (reason: acquired by AstraZeneca)
15.31
0.00 (0.00%)
Last trade price

Icosavax Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019
Revenue
0.587.81.620
Revenue Growth (YoY)
-92.54%382.80%--
Gross Profit
0.587.81.620
Selling, General & Admin
30.2334.892.661.24
Research & Development
65.4138.7817.674.16
Operating Expenses
95.6473.6620.335.4
Operating Income
-95.06-65.86-18.71-5.4
Interest Expense / Income
-3.30.150.33-0.1
Other Expense / Income
-0.96-0.19-
Pretax Income
-91.76-66.97-18.85-5.3
Net Income
-91.76-66.97-18.85-5.3
Preferred Dividends
0000.67
Net Income Common
-91.76-66.97-18.85-5.97
Shares Outstanding (Basic)
401827
Shares Outstanding (Diluted)
401827
Shares Change
121.11%700.18%-65.98%-
EPS (Basic)
-2.31-3.73-8.40-0.90
EPS (Diluted)
-2.31-3.73-8.40-0.90
Free Cash Flow
-72.79-39.55-14.22-4.57
Free Cash Flow Per Share
-1.83-2.20-6.33-0.69
Gross Margin
100.00%100.00%100.00%-
Operating Margin
-16332.99%-844.16%-1157.80%-
Profit Margin
-15765.98%-858.38%-1166.71%-
Free Cash Flow Margin
-12506.53%-506.87%-879.89%-
EBITDA
-93.22-66.74-18.52-5.4
EBITDA Margin
-16016.32%-855.40%-1146.16%-
Depreciation & Amortization
1.840.0800
EBIT
-95.06-66.82-18.52-5.4
EBIT Margin
-16332.99%-856.45%-1146.23%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).